
Am Fam Physician. 2022;105(2):131-132

Details for This Review
Study Population: Adults hospitalized with moderate to severe COVID-19 treated with remdesivir, placebo, or standard care
Efficacy End Points: All-cause mortality and need for respiratory support (high-flow oxygen, noninvasive or invasive ventilation) at up to 28 days of treatment, duration of invasive mechanical ventilation, quality of life, duration of hospitalization, intensive care unit (ICU) admission, and duration of ICU stay
Harm End Points: Any adverse event at up to 28 days of treatment
Narrative: SARS-CoV-2 has infected more than 300 million people and caused more than 5.5 million deaths worldwide.1 There has been an urgency to identify effective treatments, including antiviral medications, to decrease morbidity and mortality. Remdesivir is an antiviral drug that has been hypothesized to inhibit viral replication of RNA viruses such as SARS-CoV-2.2

Benefits | Harms |
---|---|
No one was helped: neither death nor the need for respiratory support was prevented | Unclear |
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available